Abraham Hamadeh (R-AZ)
Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026
A Republican bill with 1 Democratic cosponsor · See all 4 cosponsors
Last activity — Referred to the House Committee on Armed Services.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill directs the Secretary of Defense to submit a report to Congress regarding emerging investigational treatment options for treatment-resistant post-traumatic stress disorder. Specifically, the report must focus on data from a 2026 clinical trial involving organic whole psilocybin-containing mushrooms. The required report must cover operational relevance, safety, dosing, feasibility, and how the data applies to members of the Armed Forces and transitioning servicemembers. It also requires the Department of Defense to assess implications for force health protection, medical readiness, and suicide prevention strategies. Furthermore, the report must describe legal requirements for potential expanded access pathways involving Schedule I substances and address continuity of care between military and Veterans Health Administration medical facilities. The Assistant Secretary of Defense for Health Affairs must submit this report within 180 days of the Act's enactment in coordination with other federal health agencies.
Yes· 3 of 13
- Scored +8
Would veterans be better off under this, taking everything together?
The legislation directly focuses on investigating alternative treatments and improving continuity of care for veterans with treatment-resistant PTSD.
- Scored +7
Does this help veterans get medical care?
The bill directly assesses clinical trial data, suicide prevention strategies, and continuity of care for veterans and transitioning servicemembers dealing with PTSD.
- Scored +7
Does this increase the pay, pensions or support veterans receive?
By addressing force health protection, medical readiness, and continuity of care between military facilities and the VA, the bill supports veteran well-being.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 2(b) and Section 2(c)(1): This provision requires a report on safety, dosing, and adverse event data from clinical trials evaluating emerging treatments like whole-mushroom psilocybin for post-traumatic stress disorder. This could benefit veterans and servicemembers by pushing the government to closely examine alternative therapies when standard treatments fail.
-
Section 2(c)(2): This requires an assessment of how trial data impacts suicide prevention strategies and identifies gaps in existing treatments. This is positive because it directly targets the severe risks of chronic impairment and suicidality associated with treatment-resistant post-traumatic stress disorder.
-
Section 2(c)(5): This provision assesses considerations to ensure continuity of care for members transitioning from military medical treatment facilities to the Veterans Health Administration. This is a helpful step to ensure that healthcare, safety monitoring, and clinical oversight are not disrupted when a servicemember leaves the military.
Potential Negative Impacts for People
-
Section 2(a)(3) and Section 2(f)(2): The text notes that existing therapies are not effective for all patients, and the bill deals with investigational Schedule I substances and treatments like whole-mushroom psilocybin. Because these are still experimental investigational options, patients relying on them face uncertainties regarding actual efficacy and potential unknown adverse events until the research is fully evaluated.
-
Section 2(c)(3) and Section 2(c)(4): These sections require descriptions of complex legal and regulatory requirements for expanded access pathways involving Schedule I substances, alongside federal right-to-try pathways. Navigating these strict federal rules and coordination requirements between agencies like the Food and Drug Administration and the Drug Enforcement Administration could create bureaucratic hurdles or delays for individuals seeking immediate access to treatments.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would veterans be better off under this, taking everything together? — The legislation directly focuses on investigating alternative treatments and improving continuity of care for veterans with treatment-resistant PTSD. Would people in middle age be better off under this? — Active-duty members and middle-aged veterans suffering from treatment-resistant PTSD may benefit from the findings. Would people in their twenties and thirties be better off under this? — Younger adults serving in the Armed Forces may benefit from future mental health treatments evaluated by this bill. Would retired people be better off under this? — Retirees who are veterans could benefit from improved VA healthcare integration and mental health treatment options. Would people over 65 be better off under this? — Older veterans may also experience long-term improvements if new PTSD therapies are successfully integrated into the VA.
- Healthcare
- Does this help veterans get medical care? — The bill directly assesses clinical trial data, suicide prevention strategies, and continuity of care for veterans and transitioning servicemembers dealing with PTSD. Does this make mental health care easier to get? — The bill directs a report on emerging investigational treatments like whole-mushroom psilocybin for treatment-resistant PTSD, which could improve future mental health care options for veterans and servicemembers. Does this make health care easier to get in general? — The legislation explores expanded access pathways and right-to-try provisions for emerging treatments.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The legislation requires a detailed report to congressional defense committees on investigational medical treatments and regulatory requirements. Does this leave more decisions to the states? — The bill recognizes state-level administrative support for clinical trials, such as those enabled by Arizona. Does this give the federal government more power? — The bill tasks federal agencies like the Department of Defense and FDA with producing reports and evaluating regulatory pathways.
- National Security And Foreign Policy
- Does this increase the pay, pensions or support veterans receive? — By addressing force health protection, medical readiness, and continuity of care between military facilities and the VA, the bill supports veteran well-being.
- Education And Technology
- Does this put more money into scientific research? — The bill reviews clinical research and trial data regarding investigational treatments for mental health conditions.
- 8/3/2026
- 1 Cosponsor added.
- 6/30/2026
- Referred to the House Committee on Armed Services.
- 3 Cosponsors added.
- Introduced in House
Don BaconRepublican · Nebraska
Dan CrenshawRepublican · Texas
Jennifer KiggansRepublican · Virginia
Seth MoultonDemocrat · Massachusetts